Other variants, such as TM6SF2 E167K and MBOAT7, are linked to MASLD progression, with TM6SF2 showing a paradoxical protective effect against cardiovascular events despite worsening liver disease [159,160]. This evidence concerns the gene MBOAT7 and metabolic dysfunction-associated steatotic liver disease.